Prelude Therapeutics News and Activities

Prelude Therapeutics is a company listed under the stock ticker PRLD (US).

View the org chart displaying its 19 main executives

Most searched biographies at Prelude Therapeutics

• Kris Vaddi, Chief Executive Officer and Director
• Paul Scherer, Director
• Martin Babler, Director

Popular executive movements at Prelude Therapeutics

• Charles Morris will join the company as Chief Medical Officer on Apr. 20, 2026  (posted on April 16 2026).
• Katina Dorton has joined the company as Director  (posted on October 17 2025).

Create your alert
to follow the executive moves at Prelude Therapeutics.

Prelude Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Prelude Therapeutics

• News Releases - Prelude Therapeutics
• News Releases - Prelude Therapeutics
• News Releases - Prelude Therapeutics
• News Releases - Prelude Therapeutics
• Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results - Prelude Therapeutics
• Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology - Prelude Therapeutics
• Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference - Prelude Therapeutics
• Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May - Prelude Therapeutics
• Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Prelude Therapeutics
• Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update - Prelude Therapeutics
• View more press releases Close

Social media about Prelude Therapeutics

• Prelude Therapeutics on Wikipedia, Google News & Yahoo Finance
• Prelude Therapeutics on LinkedIn, X (Twitter) & YouTube